Government biomarker doctrine governance

Introduction

Government biomarker doctrine governance refers to the legal and institutional framework governing the collection, use, storage, interpretation, sharing, and protection of biological markers by public authorities. Biomarkers are measurable biological characteristics—such as genetic variants, proteins, hormones, metabolites, immune indicators, or physiological measurements—that can provide information about an individual's health, disease risk, biological condition, or response to treatment. Although the expression “government biomarker doctrine” is not a universally established legal doctrine, it can be understood as a developing framework derived from constitutional rights, medical law, privacy law, biotechnology regulation, public-health law, data-protection principles, and administrative accountability.

Government use of biomarkers can serve legitimate public purposes. Biomarker information may assist disease surveillance, screening programmes, environmental-health monitoring, epidemiological research, public-health emergencies, and allocation of medical resources. However, because biomarkers may reveal extremely sensitive information about individuals and families, government collection can create serious risks of surveillance, discrimination, unauthorized disclosure, and excessive state intervention.

The central legal question is therefore whether the government has sufficient legal authority to obtain and process biomarker information while respecting individual autonomy, privacy, equality, and due process.

Constitutional foundations of biomarker governance

The strongest foundation for government biomarker governance is the constitutional protection of privacy and bodily autonomy. In Justice K.S. Puttaswamy (Retd.) v. Union of India, (2017) 10 SCC 1, the Supreme Court of India recognized privacy as a fundamental right under Article 21 and emphasized bodily and informational privacy. The judgment established that state interference with privacy must satisfy requirements of legality, legitimate state purpose, proportionality, and procedural safeguards.

Biomarker collection may involve both bodily privacy and informational privacy. For example, obtaining blood, saliva, tissue, or genetic information without adequate legal authority may interfere with bodily integrity. Once the information is obtained, retaining or analysing it may interfere with informational privacy. Consequently, government biomarker programmes should have clearly defined purposes and limitations.

The proportionality principle becomes particularly important. A government cannot ordinarily justify unlimited biomarker collection merely by invoking public health or administrative efficiency. The collection should be connected to a legitimate objective, necessary for achieving that objective, and proportionate to the privacy intrusion.

Consent and lawful authority

Consent represents an important principle in biomarker governance, particularly in medical research. However, government programmes may sometimes operate under statutory authority rather than individual consent. This distinction is important because consent obtained from individuals dealing with government institutions may not always be completely voluntary.

A proper biomarker governance framework should therefore specify when consent is required and when statutory authority may replace consent. Where consent is used, individuals should understand what information is being collected, why it is being collected, how long it will be retained, and whether it will be shared with other institutions.

The Common Cause v. Union of India, (2018) 5 SCC 1 decision, although concerning passive euthanasia and medical autonomy rather than biomarkers specifically, is relevant because the Supreme Court strongly recognized individual autonomy and dignity in medical decision-making. These principles support a legal approach under which individuals retain meaningful control over highly sensitive biological information.

Data protection and biomarker information

Biomarker governance also requires strong data-protection safeguards. Biomarker information can potentially identify individuals, reveal medical conditions, indicate future disease risks, and expose information about biological relatives. Genetic information is particularly sensitive because it may have implications beyond the individual from whom the sample was obtained.

The Digital Personal Data Protection Act, 2023 provides India's broader statutory framework for processing digital personal data. Government processing must operate within the legal requirements applicable to the relevant processing activity, while sensitive biological information requires particularly careful governance from a policy perspective.

Important safeguards include:

• purpose limitation;
• data minimisation;
• security safeguards;
• restricted access;
• retention limits;
• accountability of government agencies;
• controls on secondary use;
• mechanisms for correction where applicable; and
• remedies against unlawful processing.

Biomarker databases should therefore not become permanent repositories without clearly defined legal purposes.

Equality and discrimination

Biomarker governance also has an important equality dimension. Biomarker information could potentially be used to classify individuals according to disease susceptibility, genetic characteristics, disability, or other biological attributes.

Article 14 of the Indian Constitution requires equality before law and protection against arbitrary state action. Articles 15 and 16 also restrict certain forms of discrimination. Consequently, government agencies should not use biomarker information to impose arbitrary disadvantages on individuals.

Comparative constitutional jurisprudence reinforces this principle. In S. and Marper v. United Kingdom, (2008) 48 EHRR 50, the European Court of Human Rights considered the indefinite retention of DNA profiles by police. The Court held that the indiscriminate retention of DNA information of individuals who had not been convicted violated Article 8 of the European Convention on Human Rights. The decision demonstrates that even information collected for legitimate law-enforcement purposes cannot necessarily be retained indefinitely.

Biomarkers and public-health governance

Governments may have stronger grounds for biomarker collection when dealing with serious public-health threats. Biomarkers can support disease surveillance, epidemiological research, vaccination strategies, and identification of high-risk populations.

Nevertheless, emergency powers should not eliminate legal accountability. Measures should remain connected to the public-health objective and should be subject to review, transparency, and appropriate time limitations.

The Supreme Court's reasoning in Mr. X v. Hospital Z, (1998) 8 SCC 296 is relevant to the balancing of medical confidentiality against public-health considerations. The Court recognized that confidentiality is important but is not necessarily absolute where disclosure is justified by overriding public interests.

Thus, government biomarker governance requires a balance between individual confidentiality and legitimate public-health interests.

Law-enforcement applications

Biomarkers may also be used for criminal investigation, including DNA profiling. This creates a difficult conflict between investigative interests and privacy.

In Selvi v. State of Karnataka, (2010) 7 SCC 263, the Supreme Court considered involuntary techniques such as narco-analysis, polygraph examinations, and brain-mapping. The Court emphasized personal liberty, mental privacy, and protection against compelled testimonial evidence. Although conventional biomarker testing differs from these techniques, the case provides important constitutional principles concerning compelled extraction of personal biological or cognitive information.

Government agencies should therefore distinguish between:

1. voluntary medical biomarker collection;
2. statutory public-health collection;
3. forensic DNA collection; and
4. compelled biological testing.

Each category requires its own legal safeguards.

Institutional governance and accountability

A strong biomarker governance system should not rely exclusively on the government agency collecting the information. Independent oversight is important. Regulatory institutions should establish standards governing sample collection, laboratory accuracy, cybersecurity, access controls, retention, destruction, and secondary research.

Government agencies should maintain audit trails showing who accessed biomarker information and for what purpose. Unauthorized access should attract disciplinary, civil, or criminal consequences where appropriate.

Transparency is equally important. Individuals should ordinarily be informed about the existence and purpose of major government biomarker databases, subject to narrowly defined exceptions involving legitimate security or investigative interests.

International jurisprudence

International law provides additional guidance. In S. and Marper v. United Kingdom, the European Court emphasized that biological identifiers require special safeguards because of their highly personal nature. Similarly, European data-protection principles treat genetic and health-related information as particularly sensitive categories of personal data.

The Universal Declaration on the Human Genome and Human Rights (1997) also establishes important principles concerning human dignity, non-discrimination, and protection of genetic information. Although it does not operate as a conventional domestic statute, it provides a useful normative foundation for responsible biomarker governance.

Conclusion

Government biomarker doctrine governance should be based on a careful balance between public interest and individual rights. Biomarkers can substantially improve public-health administration, scientific research, disease prevention, and forensic investigation, but their use creates significant risks because biological information can reveal deeply personal characteristics.

The emerging legal framework should therefore be founded on legality, legitimate purpose, necessity, proportionality, informed consent where appropriate, data minimisation, confidentiality, equality, independent oversight, limited retention, cybersecurity, and effective remedies.

Indian constitutional jurisprudence, particularly Puttaswamy, provides the strongest foundation for such a framework by placing privacy, dignity, autonomy, and proportionality at the centre of state action. Cases such as Selvi, Common Cause, Mr. X, and the comparative decision in S. and Marper demonstrate that government authority over biological information must remain subject to meaningful legal and constitutional constraints.